Closing bid price of common stock.

No definition available.

Name:	abio_ClosingBidPriceOfCommonStock
Namespace Prefix:	abio_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Company basis of presentation.

+ References

No definition available.

+ Details

Name:	abio_CompanyBasisOfPresentationTextualAbstract
Namespace Prefix:	abio_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Notification for delisting of shares description.

+ References

No definition available.

+ Details

Name:	abio_NotificationForDelistingOfSharesDescription
Namespace Prefix:	abio_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of patients.

+ References

No definition available.

+ Details

Name:	abio_NumberOfPatients
Namespace Prefix:	abio_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of patients company plans to enroll.

+ References

No definition available.

+ Details

Name:	abio_NumberOfPatientsCompanyPlansToEnroll
Namespace Prefix:	abio_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name:	us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	abio_ClinicalTrialsByPhaseAxis=abio_PhaseThreeHeartFailureMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_HealthCareTrustFundAxis=abio_BestTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_HealthCareTrustFundAxis=abio_GENETICAFTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	abio_ClinicalTrialsByPhaseAxis=abio_PhaseTwoBHeartFailureMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

The Company and Summary of Significant Accounting Policies (Details)		1 Months Ended		6 Months Ended
	Feb. 18, 2015 $ / shares	Jun. 30, 2015 USD ($)	Feb. 28, 2014 USD ($)	Jun. 30, 2015 USD ($) Patients	Jun. 30, 2014 USD ($)
Company Basis of Presentation (Textual) [Abstract]
Revenues				$ 0
Proceeds from the issuance of common stock				$ 37,000,000	$ 9,038,000
Notification for delisting of shares				On February 18, 2015, the Company received notification from Nasdaq of potential delisting of its shares from the Nasdaq Capital Market because the closing bid price of its common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30 days. On July 15, 2015, Nasdaq notified the Company that it had regained compliance with the applicable minimum bid price rule. Accordingly, the matter related to the notice received by the Company on February 18, 2015 was closed.
Minimum closing bid price of common stock \| $ / shares	$ 1.00
Concentrations of credit risk				$ 0
Registered Direct Offering
Company Basis of Presentation (Textual) [Abstract]
Proceeds from the issuance of common stock		$ 34,000,000	$ 7,900,000
Phase 3 heart failure (HF) trial of Gencaro \| BEST Trial
Company Basis of Presentation (Textual) [Abstract]
Number of patients \| Patients				2,708
Phase 3 heart failure (HF) trial of Gencaro \| GENETIC-AF Trial
Company Basis of Presentation (Textual) [Abstract]
Number of patients company plans to enroll \| Patients				420
Phase Two B Heart Failure \| GENETIC-AF Trial
Company Basis of Presentation (Textual) [Abstract]
Number of patients company plans to enroll \| Patients				200